QLI: AI 评分 46/100 — AI 分析 (4月 2026)

Qilian International Holding Group Limited focuses on researching, developing, and producing active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD). The company also manufactures and distributes fertilizers and sausage casings.

Key Facts: Price: $5.41 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Qilian International Holding Group, a China-based pharmaceutical company, offers a diverse portfolio of APIs, TCMDs, and agricultural products, targeting growth in both the healthcare and agricultural sectors, but faces challenges with profitability and market competition, reflected in its negative profit margin.

QLI是做什么的？

Qilian International Holding Group Limited, founded in 2019 and based in Jiuquan, China, operates within the healthcare sector, specifically in the manufacturing of specialty and generic drugs. The company's core business revolves around the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and various by-products. Its product portfolio includes licorice products like Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan licorice liquid extract, catering to pharmaceutical companies and medical preparation companies. Additionally, Qilian International produces oxytetracycline tablets and APIs for both human and veterinary use. Beyond pharmaceuticals, the company manufactures TCMD products such as Ahan antibacterial paste, heparin products, and Zhu Xiaochang sausage casings. It also offers Xiongguan organic and organic-inorganic compound fertilizers aimed at improving crop yield and soil quality. Despite its diverse product range, Qilian International faces challenges related to profitability, as indicated by its negative profit margin. The company aims to serve both the pharmaceutical and agricultural sectors within China.

QLI的投资论点是什么？

Investing in Qilian International Holding Group Limited presents a speculative opportunity, given its negative P/E ratio of -24.86 and a negative profit margin of -16.7%. The company's diverse product portfolio, spanning pharmaceuticals and agricultural products, offers potential for revenue diversification. A key value driver lies in the increasing demand for traditional Chinese medicine and organic fertilizers in China. However, the company's low gross margin of 1.3% raises concerns about its cost structure and pricing strategy. Growth catalysts include expanding its distribution network and securing partnerships with larger pharmaceutical companies. Investors should closely monitor the company's ability to improve its profitability and manage its operational costs effectively. The high beta of 1.41 suggests significant volatility, making this a high-risk, high-reward investment.

QLI在哪个行业运营？

Qilian International operates in the Drug Manufacturers - Specialty & Generic industry, a segment characterized by intense competition and pricing pressures. The Chinese pharmaceutical market is experiencing growth driven by increasing healthcare expenditure and demand for both modern and traditional medicines. The organic fertilizer market is also expanding due to government initiatives promoting sustainable agriculture. Qilian International competes with both domestic and international players, including companies like BNKK, CERC, EYEN, HEXO, and LUMO. Success in this environment requires effective cost management, product innovation, and strong distribution networks. The company's ability to navigate these challenges will determine its long-term viability and growth potential.

Drug Manufacturers - Specialty & Generic

Healthcare

QLI有哪些增长机遇？

Expansion of Traditional Chinese Medicine (TCM) Product Line: The growing popularity of TCM presents a significant opportunity for Qilian International. The global TCM market is projected to reach $48.4 billion by 2027. By investing in research and development of new TCM products and expanding its distribution channels, Qilian International can capitalize on this trend. This includes expanding the Ahan antibacterial paste product line and developing new TCM-based pharmaceuticals. Success hinges on regulatory approvals and effective marketing strategies.
Increased Demand for Organic Fertilizers: With growing awareness of sustainable agriculture practices, the demand for organic fertilizers is increasing in China. The Chinese organic fertilizer market is expected to grow significantly in the coming years. Qilian International can leverage its Xiongguan fertilizer products to capture a larger share of this market. This involves expanding production capacity, improving product quality, and strengthening its distribution network to reach more farmers. The timeline for realizing this opportunity is within the next 3-5 years.
Strategic Partnerships with Pharmaceutical Companies: Qilian International can pursue strategic partnerships with larger pharmaceutical companies to expand its market reach and access new technologies. Collaborating with established players can provide access to distribution networks, research and development capabilities, and regulatory expertise. This can accelerate the commercialization of its APIs and TCMDs. The timeline for establishing such partnerships is within the next 1-2 years.
Geographic Expansion within China: Focusing on expanding its sales and distribution network to other regions within China represents a significant growth opportunity. By targeting provinces with high demand for its products, Qilian International can increase its revenue and market share. This involves establishing new sales offices, partnering with local distributors, and tailoring its product offerings to meet the specific needs of different regions. This expansion can be phased over the next 3-5 years.
Development of New APIs: Investing in the research and development of new active pharmaceutical ingredients (APIs) can provide Qilian International with a competitive edge. By developing innovative APIs, the company can cater to unmet medical needs and capture new market segments. This requires significant investment in research and development, as well as navigating the regulatory approval process. The timeline for bringing new APIs to market is typically 3-5 years.

Market Cap of $0.04B indicates a small-cap company with potential for high growth but also higher risk.
P/E Ratio of -24.86 reflects the company's current lack of profitability, suggesting it is not generating positive earnings relative to its share price.
Profit Margin of -16.7% indicates that the company is currently operating at a loss, requiring careful monitoring of cost management and revenue generation.
Gross Margin of 1.3% is significantly lower than industry averages, highlighting potential issues with cost of goods sold or pricing strategies.
Beta of 1.41 suggests the stock is more volatile than the market, indicating higher risk and potential for larger price swings.

QLI提供哪些产品和服务？

Researches and develops active pharmaceutical ingredients (APIs).
Produces traditional Chinese medicine derivatives (TCMD).
Manufactures licorice-based pharmaceutical products.
Produces oxytetracycline tablets and APIs for human and veterinary use.
Manufactures and distributes organic and organic-inorganic compound fertilizers.
Produces Zhu Xiaochang sausage casings.

QLI如何赚钱？

Manufactures and sells APIs to pharmaceutical companies.
Develops and markets its own branded pharmaceutical products.
Produces and sells organic and inorganic fertilizers to farmers.
Sells sausage casings to food processing companies.

Pharmaceutical companies that use Qilian International's APIs to manufacture medications.
Medical preparation companies that use licorice extracts to produce oral solutions and tablets.
Farmers who purchase Qilian International's organic and organic-inorganic compound fertilizers.
Food processing companies that purchase Zhu Xiaochang sausage casings.

Established presence in the Chinese pharmaceutical and agricultural markets.
Diverse product portfolio spanning pharmaceuticals, TCMDs, and agricultural products.
Proprietary formulations for certain TCM products.
Access to natural resources, such as licorice, in the Qilian Mountains.

什么因素可能推动QLI股价上涨？

Ongoing: Expansion of distribution network within China to reach new markets.
Ongoing: Increased investment in research and development to create new APIs and TCM products.
Upcoming: Potential partnerships with larger pharmaceutical companies to expand market reach.
Ongoing: Government support for the TCM industry and sustainable agriculture practices.

QLI的主要风险是什么？

Ongoing: Intense competition in the pharmaceutical and fertilizer industries.
Potential: Fluctuations in raw material prices affecting profitability.
Potential: Changes in government regulations impacting pharmaceutical and fertilizer production.
Ongoing: Negative profit margin and low gross margin impacting financial stability.
Potential: Product liability claims related to pharmaceutical products.

QLI的核心优势是什么？

Diverse product portfolio across pharmaceuticals and agriculture.
Established presence in the Chinese market.
Access to natural resources for licorice production.
Proprietary formulations for certain TCM products.

QLI的劣势是什么？

Negative profit margin and low gross margin.
High beta indicating significant stock volatility.
Limited brand recognition compared to larger competitors.
Dependence on the Chinese market.

QLI有哪些机遇？

Expanding TCM product line to capitalize on growing demand.
Increasing sales of organic fertilizers due to sustainable agriculture trends.
Forming strategic partnerships with larger pharmaceutical companies.
Geographic expansion within China.

QLI面临哪些威胁？

Intense competition from established pharmaceutical companies.
Stringent regulatory requirements for pharmaceuticals and fertilizers.
Fluctuations in raw material prices.
Potential for product liability claims.

QLI的竞争对手是谁？

North Mountain Bancorp, Inc. — Regional bank, different industry. — (BNKK)
Cerecor Inc. — Focuses on rare diseases. — (CERC)
Eyenovia, Inc. — Specializes in ophthalmic solutions. — (EYEN)
HEXO Corp. — Cannabis company, different industry. — (HEXO)
Lumos Pharma, Inc. — Focuses on growth hormone deficiencies. — (LUMO)

Key Metrics

Price: $5.41 (-3.57%)
Market Cap: $39.0M
Volume: 330
MoonshotScore: 46/100

Company Profile

CEO: Chen Xin
Headquarters: Jiuquan, CN
Employees: 298
Founded: 2021

AI Insight

常见问题

What does Qilian International Holding Group Limited do?

Qilian International Holding Group Limited is a Chinese company that develops, manufactures, and distributes a range of pharmaceutical and agricultural products. Its pharmaceutical segment focuses on active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD), including licorice-based products and oxytetracycline. The company also produces organic and organic-inorganic compound fertilizers for the agricultural sector, as well as Zhu Xiaochang sausage casings. Qilian International aims to serve both the healthcare and agricultural markets in China.

Is QLI stock a good buy?

QLI stock presents a high-risk, high-reward investment opportunity. The company's negative P/E ratio and profit margin raise concerns about its current financial performance. However, its diverse product portfolio and potential growth in the TCM and organic fertilizer markets offer upside potential. Investors should carefully consider the company's ability to improve its profitability, manage its costs, and navigate the competitive landscape before investing. The high beta of 1.41 indicates significant volatility, making it suitable for risk-tolerant investors.

What are the main risks for QLI?

The main risks for Qilian International include intense competition in the pharmaceutical and fertilizer industries, which could pressure pricing and market share. Fluctuations in raw material prices, particularly for licorice and other key ingredients, could impact profitability. Changes in government regulations related to pharmaceutical and fertilizer production could also pose a risk. The company's negative profit margin and low gross margin highlight financial risks that need to be addressed to ensure long-term sustainability. Product liability claims are also a potential risk associated with pharmaceutical products.